TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06474312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nae Disha
Description: Nae Disha for Life is a brief, multi-component, psychosocial promotion and resilience tool developed by Emmanuel Hospital Association, New Delhi. The purpose of this research work is to evaluate the feasibility, acceptance, and effectiveness of Nae Disha for Life tool in reducing suicide ideation among youth in Bundelkhand region. This will be implemented among the targeted schools of Nowgong block, Chhatarpur district.
Study: NCT05936944

Intervention type: OTHER
Intervention: Exposure to totally artificial lighting
Description: The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting
Study: NCT05250414

Intervention type: DEVICE
Group type: OTHER
Intervention: MED-EL Cochlear Implant System
Description: Cochlear implant and audio processor
Study: NCT06456203

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AI
Description: Artificial intelligence triage and reporting system
Study: NCT05842174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipiodol
Description: Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
Study: NCT06781736

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Talking Circle intervention
Description: Talking Circle intervention
Study: NCT06785272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Description: After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].
Study: NCT06786104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIDEO-PEDS
Description: Following enrollment, parents will receive a link to view the refined video decision aid that is designed to prompt parents to think about their goals of care for their child with cancer, and then to react by engaging in communication with a trained member of the research team called the Navigator and eventually their clinical team over the course of the 9-month study duration.

Intervention type: OTHER
Group type: OTHER
Intervention: VIDEO-PEDS pilot
Description: This is the 3-month pilot version of the intervention, which will be further developed for the eventual RWCT.

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group
Description: Parents will view the Video aid and provide fascilitated feedback in an audio-recorded virtual group setting.
Study: NCT06784167

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06782529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Low Dose
Description: Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.~Total injection volume of 5ml, consisting of:~* 0.5ml triamcinolone acetonide (20mg)~* 4.5ml lidocaine (45mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide Standard Dose
Description: Subjects will receive the standard of care dose of 40mg triamcinolone acetonide~Total injection volume of 5ml, consisting of:~* 1ml triamcinolone acetonide (40mg)~* 4ml lidocaine (40mg)
Study: NCT06786780

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: Cisplatin
Description: Organoids were constructed prior to simultaneous radiochemical therapy
Study: NCT06786091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training rehabilitation
Description: The intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation is supported with written information. The exercise program is provided with supervised digital group exercise sessions twice weekly and a home exercise program 4-5 weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage i.e. 3 sets of 10-12 repetitions, 5-7 times per week.
Study: NCT06783894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise (elliptical training)
Description: twenty irritable bowel syndrome men with sexual dysfunction ( weak erection of penis or erectile dysfunction) will perform ellpitical physical activity (40 minutes on elliptical trainer three times weekly. the duration of physical activity will be 12 weeks.
Study: NCT06785831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: Participants will once daily consume predefined amount of psyllium, corresponding to 3 g of dietary fibre, for 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauerkraut
Description: Participants will once daily consume predefined amount of sauerkraut, corresponding to 3 g of dietary fibre, for 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh apples
Description: Participants will once daily consume predefined amount of fresh apples, corresponding to 3 g of dietary fibre, for 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried apples
Description: Participants will once daily consume predefined amount of dried apples, corresponding to 3 g of dietary fibre, for 28 days.
Study: NCT06783166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide 500mg
Description: Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
Study: NCT06783530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Splint Therapy with Enhanced Doctor-Patient Communication
Description: A structured communication protocol aimed at improving doctor-patient interaction and treatment adherence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint Therapy
Description: A custom-fitted occlusal splint designed to alleviate symptoms of temporomandibular disorders (TMD).
Study: NCT06785935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle knife
Description: ultrasonography-guided percutaneous A1 pulley release using a needle knife

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid: Betamethasone
Description: ultrasonography-guided corticosteroid injection under the A1 pulley
Study: NCT06785116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
Study: NCT06786949

Intervention type: OTHER
Intervention: Questionnaire
Description: All cases and controls will be contacted by telephone or e-mail and invited to participate in the study. Female workers who decide to join the study will be asked to go to their company's occupational health clinic where they will undergo administration of a questionnaire to investigate possible known and unknown risk factors for breast cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for biomarker measurement
Description: Women who give consent to undergo this phase of the study will be called back to the center and will be asked to provide a blood sample
Study: NCT06784999

Intervention type: DRUG
Group type: OTHER
Intervention: sufentanil
Description: 1. Intravenous sufentanil starting at a dose of 0.5 mcg/kg/min hr ideal body weight (IBW) at the beginning of the case, prior to surgical incision, with a discontinuation of the infusion when the surgical microscope is removed from the patient field and the closure of the incision(s) begins. (n=64)

Intervention type: DRUG
Group type: OTHER
Intervention: methadone
Description: 2. Intravenous methadone of 0.2 mg/kg IBW up to a maximum dose of 20mg, rounded to the nearest milligram. The methadone will be given at the beginning of the case, prior to surgical incision. n=64)
Study: NCT06782685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposoma
Description: Exploration started with 50mg/m\^2 dose, preset 50mg/m\^2, 60mg/m\^2, 2 dose groups, IV infusion 90min, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Exploration started with 60mg/m\^2 dose, preset 60mg/m\^2, 85mg/m\^2, 2 dose groups, IV infusion, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg，i.v.，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg，i.v.，d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400mg/m\^2, i.v.，46h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV
Description: 400mg/m\^2, i.v.，d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Liposomal
Description: 70mg/m\^2, i.v.，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal
Description: Phase II recommended dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Phase II recommended dose
Study: NCT06785909

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment of postural control, body perception, psychosocial factors and inflammation
Description: Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception, psychosocial factors (incl. fear of movement, pain catastrophizing, sense of coherence, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress) and inflammatory mediators.
Study: NCT06784778

Intervention type: DIAGNOSTIC_TEST
Intervention: PBMC Kinase Activity Profile
Description: Kinase activity profile will be correlated to the observed clinical outcome parameters (including survival and toxicity associated with the therapy) of standard of care treatments

Intervention type: DIAGNOSTIC_TEST
Intervention: PBMC Kinase Activity Profile
Description: Kinase activity profile will be correlated to the observed clinical outcome parameters (including survival and toxicity associated with the therapy) of standard of care treatments
Study: NCT06785311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Native Spirit After-School Program
Description: Native Spirit is a culturally-grounded after-school program that is community-specific. The program is 10-sessions/weeks long and each session is 1.5-2 hours in duration. Each session is guided by a local cultural knowledge holder and is focused on a different cultural value and accompanying cultural practice. Native Spirit aims to promote self-esteem, cultural efficacy, awareness of cultural connectedness, and resilience while preventing and/or slow down the initiation of substance use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Native Spirit After-School Program
Description: Native Spirit is a culturally-grounded after-school program that is community-specific. The program is 10-sessions/weeks long and each session is 1.5-2 hours in duration. Each session is guided by a local cultural knowledge holder and is focused on a different cultural value and accompanying cultural practice. Native Spirit aims to promote self-esteem, cultural efficacy, awareness of cultural connectedness, and resilience while preventing and/or slow down the initiation of substance use.
Study: NCT06787651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIMA-SVG
Description: Saphenous vein grafts (SVGs) are connected to the right internal mammary artery (RIMA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ao-SVG
Description: The ascending aorta is clamped, and SVGs are anastomosed to the aorta.
Study: NCT06787833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: to complete a questionnaire including socio-demographic data, Perceived Stress Scale (PSS-14), and Coronavirus Anxiety Scale (CAS) before patient admission (T1). The students were asked to complete the same questionnaire at the end of the day after working for 2 days (T2) and in the morning on the 5th day of their study before seeing patients (T3).The same questionnaire was refilled at the end of the week in which music was played (T4).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music
Description: Each of the students participating in the study was given disposable headphones every day during the week of music listening. In this study, Beethoven's Moonlight Sonata (1 hour 2 minutes)23,55, Mozart's Serenata Notturna KV239 (12.50 minutes)18,19, and Pachelbel's Canon in D major (6.16 minutes)24,25 were used. It was shared with the students via WhatsApp and they were allowed to listen to this music on their phones for 1 week (2 hours on average) during the study period.
Study: NCT06552234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Repotrectinib 160 mg BID, until progression or unacceptable toxicity
Study: NCT04685577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle)
Description: Participants will receive vehicle with out the investigational product
Study: NCT06779981

Intervention type: OTHER
Intervention: Nasopharyngeal swabs
Description: Completion of an electronic Diary (eDiary) and collection of nasopharyngeal swabs in case the subject experiences ILI symptoms
Study: NCT05738486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV
Study: NCT05607719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevespi
Description: Two puffs twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevespi
Description: Two puffs twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bretzri
Description: Two puffs twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bretzri
Description: Two puffs twice a day
Study: NCT06358755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Multiple Segments lenses
Description: Defocus Incorporated Multiple Segments lenses that provide optical defocus for myopia control will be given to this group of participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single vision spectacle lenses
Description: Single vision spectacle lenses will be given to this group of participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose atropine
Description: 0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
Study: NCT06111898

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT06358755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose atropine
Description: 0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
Study: NCT06145997

Intervention type: OTHER
Intervention: Acupuncture therapy
Description: Acupuncture therapy (AT) is delivered by Licensed Acupuncturists (LAcs). Treatment plans are determined according to each patient's presentation and resulting traditional East Asian medicine (TEAM) differential diagnosis. TEAM therapeutics include AT, Chinese herbal medicine (CHM), Kampo herbal medicine, gua sha, tui na, cupping and lifestyle advice. All TEAM therapeutics are allowed in this study because it is a pragmatic, effectiveness study.
Study: NCT05643729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofin
Description: Intravenous Infusion (IV) of Zofin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Infusion of sterile saline
Study: NCT06582589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healsea Children
Description: Subjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out
Study: NCT05097287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for injection subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection subcutaneous
Study: NCT06784479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam and Propofol
Description: Application of Remimazolam and Propofol to induce sleep

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Application of Propofol to induce sleep

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and propofol
Description: Application of Midazolam and Propofol to induce sleep
Study: NCT06785584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: receive neoadjuvant treatment with ensartinib 225 mg once a day, po. for 2 consecutive cycles (56 days) to evaluate possibility of surgery, or discontinue the treatment because of disease recurrence or intolerable toxicity
Study: NCT06787664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06786572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Brief mindfulness training focused on management of unwanted internal sensations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interoceptive exposure
Description: Cognitive behavioral therapy focused in interoceptive exposure to unwanted internal sensations
Study: NCT06787404

Intervention type: DRUG
Intervention: Ephedrine
Description: 5 milligrams of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.

Intervention type: DRUG
Intervention: Noradrenalin
Description: 5 micrograms of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
Study: NCT06787482

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ACE Retino
Description: 1 ml sublingually self administer / 4 times/day for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACE Retino
Description: 1 ml sublingually self administer / 4 times/day for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACE Retino
Description: 1 ml sublingually 4 times daily for 6 months
Study: NCT05509998

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Method (SM)
Description: All consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate.
Study: NCT06785532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive Neurostimulation (RNS)
Description: The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.